This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

A Phase 1 Safety Study of TG100801 Eye Drops in Healthy Volunteers

This study has been completed.
Information provided by:
TargeGen Identifier:
First received: December 20, 2006
Last updated: July 27, 2007
Last verified: July 2007

The formation of new blood vessels (angiogenesis), blood vessel leakage, and inflammation contribute to the progression of the eye disease, age-related macular degeneration (AMD), which is the leading cause of irreversible, severe loss of vision in people 55 years of age and older in the developed world. TG100801 is a new drug that inhibits ocular angiogenesis, vascular leak, and inflammation in laboratory studies, and may have great utility in the treatment of diseases such as AMD.

The purpose of this study is to assess the safety, ocular tolerability, and blood pharmacokinetics of TG100801 at escalating doses in healthy volunteers.

Condition Intervention Phase
Macular Degeneration Diabetic Retinopathy Drug: TG100801 Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Phase 1, Double-Masked, Placebo-Controlled, Dose-Escalation Study (in Two Parts) of TG100801 and a Colored Vehicle in Adult Healthy Volunteers

Resource links provided by NLM:

Further study details as provided by TargeGen:

Primary Outcome Measures:
  • Part A: Safety & tolerability of vehicle & 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 1 day, assessed up to 5 (+/- 1) days following dosing.
  • Part B: Safety & tolerability of 2 concentrations of TG100801 (ophthalmic examinations, ocular comfort ratings, ocular/systemic adverse events, lab tests) when administered twice a day for 14 days, assessed up to 7-14 days following dosing.

Secondary Outcome Measures:
  • Systemic pharmacokinetics (Part B only)

Enrollment: 44
Study Start Date: November 2006
Study Completion Date: February 2007

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

Male or female healthy volunteers who meet the following criteria are eligible for inclusion in the study. Subjects who participate in Part A of the study may not participate in Part B.

  • Age > 18 years (50% of subjects must be > 40 years of age).
  • Corrected visual acuity > 20/25 in both eyes.
  • Intraocular pressure (IOP) < 21 mm Hg, with a difference between eyes of < 4 mm Hg.
  • Ability to tolerate and self-administer vehicle eye drops to the satisfaction of study staff.
  • Tolerance of a commercially available benzalkonium chloride-preserved, artificial tear solution in one eye.
  • Normal slit lamp exam and dilated fundoscopic exam within 2 weeks of dosing.
  • Normal clinical laboratory profiles, defined as complete blood count, serum chemistry, and urinalysis values within the normal range.
  • Willing to abstain from the concomitant use of ocular or systemic medication (excluding acetaminophen and multivitamins) from 2 weeks prior to start of study dosing until study completion.
  • Willing to comply with scheduled visits, treatment plans, laboratory assessments, and other study-related procedures.
  • Provide written informed consent to participate.

Exclusion Criteria:

Subjects who meet any of the following criteria are excluded from the study:

  • History of ocular surgery, trauma, or chronic ocular disease.
  • Current use of contact lenses or discontinuation of contact lens use within 2 weeks of the first dosing day.
  • Any ocular abnormalities or ocular symptoms (defined as a non-zero score on assessment scales).
  • Use of ocular agents (including eye drops) within the past 2 months or anticipated use of ocular agents during the study period.
  • Systemic corticosteroid use within the past 6 months.
  • History or evidence of ocular infection, inflammation, blepharitis, or conjunctivitis with 2 months; history of herpes simplex keratitis.
  • Presence of a nonhealing wound, ulcer, fracture, or any medical condition associated with bleeding.
  • Use of antimitotic or antimetabolite therapy within 2 months of enrollment.
  • Loss, donation, or removal of 400 mL or more of blood within the past 2 months.
  • Women who are pregnant or breastfeeding, or nonsterile or premenopausal women who refuse to use two proven methods of contraception during and for at least 2 weeks following the final dose of study drug.
  • Enrollment in another investigational drug or device study within 2 months of study entry.
  • Ongoing cardiac arrhythmias or prolongation of the QTc interval to > 450 msec for males or > 470 msec for females.
  • Known liver, kidney, cardiovascular, neurologic, or pulmonary disease; treated or untreated hypertension; current or history of drug or alcohol abuse.
  • Known human immunodeficiency virus- or acquired immunodeficiency syndrome-related illness.
  • Known intolerance to any excipients in the study drug formulation.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or study drug administration, would affect the subject's ability to follow study-related procedures, or may interfere with the interpretation of study results and, in the investigator's opinion, would make the patient inappropriate for entry into this study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00414999

United States, Kansas
Quintiles Phase One Services, Inc.
Lenexa, Kansas, United States, 66219
Sponsors and Collaborators
Principal Investigator: Philip T Leese, M.D. Quintiles Phase One Services, Inc.
  More Information

Additional Information: Identifier: NCT00414999     History of Changes
Other Study ID Numbers: OPH-TG100801-001
Study First Received: December 20, 2006
Last Updated: July 27, 2007

Keywords provided by TargeGen:
Macular degeneration
Vascular diseases
Retinal disorders
Macular edema

Additional relevant MeSH terms:
Macular Degeneration
Diabetic Retinopathy
Retinal Degeneration
Retinal Diseases
Eye Diseases
Diabetic Angiopathies
Vascular Diseases
Cardiovascular Diseases
Diabetes Complications
Diabetes Mellitus
Endocrine System Diseases processed this record on September 25, 2017